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Abstract
Background: In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic
marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal
antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring
the identification of additional targets to overcome resistance. In this study, we have combined computational
simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network
to define potential therapeutic strategies for de novo trastuzumab resistant breast cancer.
Results: First, we employed Boolean logic to model regulatory interactions and simulated single and multiple protein
loss-of-functions. Then, our simulation results were tested experimentally by producing single and double knockdowns
of the network components and measuring their effects on G1/S transition during cell cycle progression. Combinatorial
targeting of ERBB2 and EGFR did not affect the response to trastuzumab in de novo resistant cells, which might be due
to decoupling of receptor activation and cell cycle progression. Furthermore, examination of c-MYC in resistant as well
as in sensitive cell lines, using a specific chemical inhibitor of c-MYC (alone or in combination with trastuzumab),
demonstrated that both trastuzumab sensitive and resistant cells responded to c-MYC perturbation.
Conclusion: In this study, we connected ERBB signaling with G1/S transition of the cell cycle via two major cell signaling
pathways and two key transcription factors, to model an interaction network that allows for the identification of novel
targets in the treatment of trastuzumab resistant breast cancer. Applying this new strategy, we found that, in contrast to
trastuzumab sensitive breast cancer cells, combinatorial targeting of ERBB receptors or of key signaling intermediates
does not have potential for treatment of de novo trastuzumab resistant cells. Instead, c-MYC was identified as a novel
potential target protein in breast cancer cells.
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Background
Anticancer drugs which are in clinical use show their effect
by acting as non-selective anti-proliferative agents which
kill also the proliferating normal cells in the tumor micro-
environment [1]. The past few decades witnessed the
development of targeted therapies including monoclonal
antibodies, which aim at targeting certain antigens
expressed on the surface of cancer cells with high specifi-
city. In particular, adding trastuzumab, a recombinant
humanized monoclonal antibody directed against the
ectodomain of the receptor tyrosine kinase ERBB2, to reg-
imens containing existing chemotherapeutic agents has
significantly improved clinical outcomes for breast cancer
patients. However, de novo and acquired resistance to tar-
geted therapeutics are common and the next challenges
for the contemporary cancer researchers [2].
The ERBB family of receptor tyrosine kinases is composed
of four receptors that have the ability to form homo- and
heterodimers, and couple binding of extracellular growth
factors to intracellular signal transduction pathways [3,4].
ERBB2, the main player of the ERBB network, does not
show any ligand binding activity, but has high dimeriza-
tion affinity [5,6]. The abnormal activation of ERBB recep-
tors through gene amplification, mutations, or protein
overexpression has been linked to breast cancer prognosis
[7]. Trastuzumab is administrated to ERBB2-overexpress-
ing breast cancer patients [8,9]. The drug shows its effect
by inducing antibody-dependent cellular cytotoxicity
(ADCC), disrupting the downstream signaling of ERBB2
and also resulting in G1/S cell cycle arrest [10]. However,
the response rate to trastuzumab is rather low, with a
range from 12% to 34% having been reported for a
median duration of 9 months [11,12]. Hence, at least two
third of the patients are de novo resistant. On the cellular
level, this might be caused by cancer cells being able to
overcome cell cycle arrest despite targeting the ERBB2
receptor. Therefore, additional targets have to be identi-
fied, which should avoid bypass of cell cycle arrest mech-
anisms.
The cell cycle of eukaryotic organisms is tightly regulated
by the cyclin-dependent kinases (CDKs) and their activa-
tion partners, cyclins [13], which lead cells through the
well-ordered G1-, S-, G2-, and M-phases. It has been
shown that ERBB2 regulates G1/S transition during cell
cycle progression by modulating the activity of the Cyclin
D, Cyclin E/CDK complex, the c-MYC oncogene, and the
p27 kinase inhibitor [7,14]. The restriction points within
different cell cycle phases represent key checkpoints,
where the critical decisions are made for the cells to
divide. At the G1/S restriction point of the cell cycle, cells
are committed to enter S phase where DNA replication
takes place [15]. This process is regulated by Cyclin D/
CDK4/6 and Cyclin E/CDK2 complexes, which phospho-
rylate and thereby inactivate tumor suppressor retinoblas-
toma protein pRB [16-18]. Hyperphosphorylation of pRB
results in the release of the E2F transcription factor that
then initiates the transcription of essential genes for DNA
replication [19]. In both normal and tumor cells, pRB
oscillates between an active (hypophosphorylated) state
in early G1 and an inactive (hyperphosphorylated) state
in the late G1, S and G2/M phases [18]. Therefore, phos-
phorylation and subsequent inactivation of pRB repre-
sents a key event governing cell proliferation.
There have been few studies which applied systems biol-
ogy approaches to identify novel markers [20] and to
define drug target networks in human cancer and other
pathologies [21]. In this study, we focused on the regula-
tion of pRB through ERBB-receptor signaling at a network
level in a de novo trastuzumab resistant cell system to iden-
tify new potential perturbation points leading to cell cycle
arrest. Instead of single candidate gene approach, which
generally examines the role of a single protein considering
it either in conjunction with a second protein or regard-
less to other proteins, we applied a systems biology
approach to identify the role of each component in the
context of protein interaction networks. This strategy is
motivated by the fact that cells react to perturbation of a
single protein by taking advantage of using alternative
ways to keep the system robust. In drug resistance, these
alternative ways allow bypassing the inhibitory effect of
drug treatment. Therefore, in order to find the uncommon
perturbations to which cells cannot find an efficient way
to react, we first integrated published data to build the
protein network for ERBB-receptor regulated cell cycle
progression, then combined qualitative dynamical mode-
ling and robust experimental approaches, and finally pre-
dicted suitable and efficient targets for individual or
combinatorial treatments in de novo trastuzumab resist-
ance in breast cancer as a model system.
We used the Boolean logical framework for the dynamical
modeling and analysis of the biological network. This
framework simplifies the regulatory activity of proteins by
considering them as all or none devices. More precisely,
each protein is defined as being either active (value 1) or
inactive (value 0) depending on its abundance or activity
level. We selected 18 proteins connecting ERBB receptor
signaling to the G1/S transition of cell cycle, and defined
logical rules to describe their regulations with regard to lit-
erature information. Modeling and loss of function simu-
lations of the network proteins were performed using the
modeling and simulation software GINsim [22,23]http://
gin.univ-mrs.fr/GINsim.
Experimental perturbations of each network element
using RNAi and following measurements of their effects
on the output protein allowed us to compare simulationsBMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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with the experimental results. Quantitative measurements
of protein abundance and activation states using reverse
phase protein arrays (RPPA) [24,25] enabled us to reverse
engineer the interactions of proteins in the cell system we
used, and to compare the experimental network data with
published results of single protein analysis. Utilizing spe-
cific inhibitors against potential targets alone or in combi-
nation with trastuzumab, we further validated the RNAi
experiments and finally defined potential future therapeu-
tic strategies.
Results
Characterization of the de novo trastuzumab resistant cell 
system
We first identified a suitable de novo trastuzumab resistant
cell system as prerequisite for studying the ERBB-receptor
regulated network. This cell system should have high
ERBB2 expression but be resistant to trastuzumab treat-
ment. To this end, we first analyzed several breast carci-
noma cell lines and the normal epithelial MCF-12A cell
line for their expression of ERBB family receptors at
mRNA and protein levels, respectively (Figure 1A and 1B).
HCC1954 cells, like SK-BR-3 and BT474 cells, express
high levels of EGFR (ERBB1) and ERBB2 receptors, but
have low levels of ERBB3. ERBB4 receptor expression was
not detected in the HCC1954 cell line.
Next, we examined the response to trastuzumab treatment
of breast carcinoma cells with high ERBB2 expression
(HCC1954 and SK-BR-3) as compared to cells with low
ERBB2 level (MCF-7) in a viability assay (Figure 1C). Cells
were treated with or without trastuzumab and cell viabil-
ity was assayed over time to observe the effect of the drug.
We further tested different concentrations of trastuzumab
to rule out the possibility that the resistance of cell system
could have been due to insufficient amounts of trastuzu-
mab being present in the assay (Additional file 1, Figure
1A). While SK-BR-3 cells responded to trastuzumab start-
ing from day two, HCC1954 cells were resistant, as they
did not show any response to the drug over four days.
Lastly, we verified the resistance of HCC1954 cells to tras-
tuzumab in 3-D cell culture (Figure 1D). After eight days
of treatment, HCC1954 cells were still growing in a large
cluster-like structure that was similar to untreated
HCC1954 cells, whereas SK-BR-3 cells were sensitive to
trastuzumab also in 3-D culture. We could exclude that
the resistance phenotype of HCC1954 cells was due to a
higher or lower ERBB2 expression level compared to sen-
sitive SK-BR-3 cells (Additional file 1, Figure 1B). Further-
more, to rule out the potential impact of possible
mutations in the ERBB2 protein on resistance phenotype
of the HCC1954 cells, the ERBB2 gene sequence was veri-
fied by sequencing and no mutation was found. Hence,
HCC1954 cells were chosen as a de novo trastuzumab
resistant model cell system in this study.
Determination of experimental output
Next, we characterized HCC1954 cells with regard to G1/
S progression by measuring the levels of pRB phosphor-
ylation, and of cell cycle proteins by comparing MOCK
(only lipofectamine transfection reagent) and CDK4
siRNA transfected cells. After synchronization, we stimu-
lated the cells with EGF. Starting from "0 hour (no EGF)",
cells were lysed at different time points and proteins of
interest were detected with specific antibodies (Figure
2A). CDK4 knockdown was efficient, as no residual pro-
tein was visible on the blot. Due to Dif-3 treatment, which
degrades Cyclin D1 at both mRNA and protein levels [26],
the level of Cyclin D1 was low at 0 h while it increased
upon continuous EGF stimulation. After 6 h of EGF stim-
ulation, Cyclin D1 expression remained constant until 24
hours in both MOCK-treated cells and after CDK4 knock-
down. For the MOCK control, a gradual increase in the
Cyclin E1 level was observed, starting from EGF stimula-
tion (0 hour) to 18 hours. In contrast, Cyclin E1 expres-
sion did not change from 0 h to 18 h after CDK4
knockdown. Surprisingly, we observed a reduction also of
CDK2 in the CDK4-siRNA treated cells, starting at 6 h.
This might be due to the partnering of CDK2 with Cyclin
E1, whose level did not increase in case of CDK4 knock-
down.
We found the phosphorylation of pRB (Ser 807/811), our
marker for G1/S transition, to be delayed and the pRB
expression level to be decreased after CDK4 knockdown,
as compared to the MOCK control. Hence, we next quan-
tified the phosphorylation level of pRB (Figure 2B) in the
same lysates using reverse phase protein arrays (RPPA).
The phosphorylation level of pRB was found to be low in
the growth-arrested cells and induction of pRB phosphor-
ylation from 6 to 12 hours did not occur abruptly for
CDK4 knockdown compared to MOCK. These data dem-
onstrate that phosphorylation of pRB at the transition
point can be quantified by RPPA as an output of EGF stim-
ulation.
Literature-based Boolean network of G1/S transition
The initial network of G1/S transition was built by extract-
ing information from the literature about interactions
between proteins involved in receptor tyrosine kinase-reg-
ulated cell cycle progression (Additional file 1, Table 1).
The resulting network encompasses 18 proteins, includ-
ing EGF as stimulus, homo- and heterodimers of ERBB
family members, tyrosine kinase receptor IGF-1R, key
transcription factors (ER-α and c-MYC), key signaling
intermediates (AKT1 and MEK1), and G1/S transition cyc-
lins, CDKs and CDK inhibitors (Figure 3). Upon activa-
tion, members of the ERBB family of tyrosine kinasesBMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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Characterization of breast cell lines for trastuzumab resistance/sensitivity Figure 1
Characterization of breast cell lines for trastuzumab resistance/sensitivity. A. qRT-PCR to determine ERBB recep-
tor family expression at mRNA level in MCF-12A normal breast epithelial cells and in five breast carcinoma cells. B. Western 
blots showing the expression level of ERBB family receptors. HCC1954 cells express high levels of ERBB1 and ERBB2 recep-
tors, but low level of ERBB3 and no ERBB4. β-actin was used as loading control. C. WST-1 cell viability assay to assess the 
resistance of breast carcinoma cells to trastuzumab (100 nM). Compared to SK-BR-3 cells, with high level of ERBB2 receptors, 
HCC1954 cells are resistant to trastuzumab (100 nM) over 4 days. D. Verification of resistance of HCC1954 cells to trastuzu-
mab compared to sensitive SK-BR-3 cells in 3-dimensional cell culture. Photos were taken after eight days of trastuzumab 
treatment.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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form homo- and heterodimers. For HCC1954 cells, six
different such dimers are possible as ERBB4 is not
expressed in this cell line. The dimers ERBB1/ERBB2,
ERBB1/ERBB3 and ERBB2/ERBB3 were represented as
specific nodes in the network. Homodimers were implic-
itly represented by the corresponding protein nodes. Since
no ligand is known for ERBB2 homodimers [27] and as
ERBB3 homodimers have a defective tyrosine kinase
domain [28], the corresponding nodes are unable to acti-
vate the ERBB targets AKT1 and MEK1. The effects of the
combinations of interactions on the activity of each pro-
tein was defined in terms of logical rules using the
Boolean operators AND, OR, and NOT. Table 1 lists these
Boolean rules for the network components, and data sup-
porting the rules is provided in the Additional file 1, Table
1. We then utilized the modeling and simulation software
GINsim [23] to implement these rules into a computa-
tional model. Figure 3 shows the resulting logical regula-
tory graph for the ERBB receptor-regulated G1/S transition
protein network. Normal arrows denote positive regula-
tions, which are either through phosphorylation, tran-
scriptional activation, or physical interaction (e.g,.
complex formation). Blunt-ended arrows denote negative
regulations. The numbers associated with each edge refers
to the respective publications providing experimental
data in support of the corresponding regulatory interac-
tion (Additional file 1, Table 1).
Simulation of loss-of-functions
For loss-of-function simulations, we performed in silico
knockdowns of the network proteins by fixing the level of
the perturbed element to "0", meaning that the corre-
sponding protein was always "inactive" (Additional file 1,
Figure 2). Each simulation was performed for specific ini-
tial protein states, matching the biological and experi-
mental conditions (for several proteins, we considered
both possible values). For example, the initial states of
p21 and p27, both of which being CDK inhibitors, were
set to "1" because, in G0/G1 arrested cells, the expression
levels of these inhibitors are high and their levels decrease
(due to their degradation in proteasomes) once cells
progress through S phase [29]. To represent continuous
EGF simulation, the initial values of ERBB nodes were set
to "1". Since the cells had been synchronized with Dif-3,
which degrades Cyclin D1, the initial level of Cyclin D1
was set to "0". Using the resulting initial states, we com-
puted all possible state transitions and iterated until we
finally obtained a unique "stable state" in which the level
of each protein was fixed (details about knockdown sim-
ulations can be found in Materials and Methods section).
Proof of principle experiments for the determination of G1/S transition point in trastuzumab resistant HCC1954 cells Figure 2
Proof of principle experiments for the determination of G1/S transition point in trastuzumab resistant 
HCC1954 cells. A. Western blots showing the expression and activation of key G1/S proteins. Cells were treated either only 
with Lipofectamine (MOCK) or with 20 nM CDK4 siRNA for 24 hours. Then, cells were synchronized for 24 hours and subse-
quently stimulated with 25 ng/ml EGF for 6, 12, 18 or 24 hours. Cell lysates were applied to immunoblotting. B. Reverse Phase 
Protein Array (RPPA) showing the phosphorylation state of pRB protein (Ser 807/811). The same lysates (from A) were 
applied to RPPA. The upper panel shows the read-out of antibody signal at near infra-red range for phospho-pRB antibody with 
four replicates. The lower panel shows the graphical representation of phospho-pRB antibody signal intensity for two different 
conditions and for four time points. Signals were normalized to 0 hour MOCK sample.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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Table 2 summarizes the outcomes of the simulations. Out
of 17 loss-of-function simulations, a significant decrease
of pRB phosphorylation (pRB is predominantly in its
hyphophosphorylated form and cells do not progress
through G1/S transition: pRB = 0) was predicted for
CDK4, Cyclin D1, and CDK6 loss of functions. For the
ERBB1_2 and ERBB1_3 knockdowns, we obtained two
possible stable states characterized by pRB = 0 and 1 that
should be resolved with experimental results. The loss-of-
function simulations for all other network proteins
resulted in the preservation of pRB phosphorylation (pRB
= 1), thus tentatively enabling G1/S transition.
Furthermore, we have also simulated the loss-of-function
of multiple proteins (all double and many triple knock-
downs) (Additional file 2, Table 1). We have observed
that if one protein knockdown gives pRB = 0, the combi-
nation of any other protein knockdown with this one also
gives pRB = 0 (e.g. ER-α knockdown gives pRB = 0 and ER-
α+AKT1 knockdown also gives pRB = 0) and we have ver-
ified this experimentally as well (Additional file 2, Table
2). We have also simulated the knockdown of all three
receptors at the same time (ERBB1_2_3) and it resulted in
2 stables states with pRB = 1 or 0 (Additional file 2, Table
1).
Assessment of siRNA knockdown efficiency and specificity 
for experimental testing of simulations
In order to validate the simulations having been per-
formed for various possible loss of functions, we utilized
RNAi to experimentally induce knockdown of the corre-
sponding proteins. First, we validated the siRNAs accord-
ing to their knockdown efficiency at both mRNA and
protein levels by qRT-PCR and Western blotting, respec-
tively (Figure 4A and 4B). We obtained at least 70%
knockdown at mRNA level for all the network proteins
(Figure 4A) and for most a similar knockdown also at the
protein level (Figure 4B), both in single and combinato-
rial RNAi settings [24]. Because of the high level of
sequence conservation among ERBB family receptors
[27], it was imperative to test for a potential cross-reactiv-
ity of ERBB receptor siRNAs (Figure 4C and 4D). To this
end, we compared the effects of the pools of four siRNAs
for every gene with those of individual siRNAs. Neither
pools nor individual siRNAs were found to have cross-
reactivity (Figure 4C and 4D).
In the combinatorial RNAi settings, the levels of the ERBB
proteins in the EGFR/ERBB2, EGFR/ERBB3, and ERBB2/
ERBB3 heterodimers were efficiently downregulated (Fig-
ure 4B). While the EGFR level was drastically reduced
when we applied double knockdown of EGFR/ERBB2,
EGFR/ERBB3, and ERBB2/ERBB3 (Figure 4B), the EGFR
protein was stable in the single knockdown with EGFR
siRNA although this treatment resulted in more than 80%
knockdown at the mRNA level (Figure 4A). However,
knockdown of the ERBB2 receptor resulted in a substan-
tial decrease of EGFR at the protein level. With respect to
the qRT-PCR results, we can exclude that this effect could
be due to a cross-reaction of the ERBB2 siRNA (Figure
4C). Therefore, we hypothesize an indispensable partner-
ing of ERBB2 and EGFR in ERBB2 overexpressing cells
(Figure 4D), and assume that the EGFR receptor protein is
efficiently stabilized that way. This hypothesis was sup-
ported by similar observations made in ERBB2 overex-
pressing SK-BR-3 cells, but not in MDA-MB-231 having
low ERBB2 expression (Additional file 1, Figure 3).
Experimental validation of loss-of-function simulations
Next, we designed a series of in vitro experiments using the
validated conditions described above to assess the results
from loss of function simulations. Lysates of three biolog-
ical replicates were analyzed with RPPA using four techni-
cal replicates of each. The signal intensity of
phosphorylated pRB was measured in the near-infrared
range (NIR) for each knockdown at two time points (0 h
and 12 h). As a negative control, we utilized MOCK sam-
ples which had not been stimulated with EGF. Results
were compared to MOCK samples (reference sample),
which had been stimulated with EGF, and the significance
of the impact on pRB phosphorylation was tested using
Table 1: Boolean rules for the activation of each component of 
the network presented in Figure 3.
Target Logical rules for the activation of target
ERBB1 EGF
ERBB2 EGF
ERBB3 EGF
ERBB1_2 ERBB1 Λ ERBB2
ERBB1_3 ERBB1 Λ ERBB3
ERBB2_3 ERBB2 Λ ERBB3
IGF1R (ER-α V AKT1) Λ !ERBB2_3
ER-α AKT1 V MEK1
c-MYC AKT1 V MEK1 V ER-α
AKT1 ERBB1 V ERBB1_2 V ERBB1_3 V ERBB2_3 V IGF1R
MEK1 ERBB1 V ERBB1_2 V ERBB1_3 V ERBB2_3 V IGF1R
CDK2 Cyclin E1 Λ !p21 Λ !p27
CDK4 Cyclin D1 Λ !p21 Λ !p27
CDK6 Cyclin D1
Cyclin D1 AKT1 V MEK1 V ER-α V c-MYC
Cyclin D1* ER-α Λ c-MYC Λ (AKT1 V MEK1)
Cyclin E1 c-MYC
p21 ER-α Λ !AKT1 Λ !c-MYC Λ !CDK4
p27 ER-α Λ !CDK4 Λ !CDK2 Λ !AKT1 Λ !c-MYC
pRB (CDK4 Λ CDK6)V (CDK4 Λ CDK6 Λ CDK2)
These rules were derived from the references listed in the Additional 
file 1, Table 1. The refined rules for Cyclin D1 are shown with "*". 
Symbols "Λ": AND, "V": OR and "!": NOTBMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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ERBB receptor regulated G1/S transition network derived from published data Figure 3
ERBB receptor regulated G1/S transition network derived from published data. ERBB receptors are functional (i.e. 
able to transmit signal to downstream proteins) only when they form heterodimers, except for ERBB1, which is also functional 
as a homodimer. The number associated with each arrow indicates the reference from which the corresponding interaction 
was extracted (a list of these references is provided in the Additional file 1, Table 1). Normal arrows denote positive regula-
tions, whereas blunt arrows denote negative regulations. These interactions correspond to transcriptional regulations, post-
transcriptional modifications, or physical interaction. EGF constitutes the input and pRB protein represents the output of the 
network.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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the ANOVA method. Box plots of the knockdown effect
on pRB phosphorylation are shown in Figure 5A. We clas-
sified effects as "1" in cases where the knockdown of a spe-
cific protein had resulted in a phosphorylation profile
similar to the MOCK profile at 12 h, and no significant
change of the pRB phosphorylation state had been
observed. Conversely, if the knockdown resulted in a sig-
nificantly lower pRB phosphorylation level compared to
MOCK (FDR < 1%), the effect was classified as "0", mean-
ing that a significant change of the pRB phosphorylation
state was observed. The results demonstrated that knock-
downs of CDK4, CDK6, Cyclin D1, Cyclin E1, ER-α, c-
MYC, ERBB1, ERBB1_2, and IGF-1R indeed resulted in a
significant hypophosphorylation of pRB.
Simulation of loss-of-function of all three receptors
(ERB1_2_3) had resulted in two stable states for pRB: "1"
and "0". Experimentally, we have shown that knockdown
of all three receptors resulted in pRB = 1 suggesting that
combinatorial targeting of ERBB receptors may not be
beneficial to overcome resistance in de novo trastuzumab
resistant cells (Additional file 2, Table 2).
To confirm the effect of knockdowns on G1/S transition at
the DNA level, we measured incorporation of 7-AAD into
the DNA of single cells by flow cytometry 18 hours after
EGF stimulation (Figure 5B). The fractions of cells in G1-
and in S phases were taken to calculate the G1/S ratio for
each knockdown. We regarded gene knockdowns having
similar effects as MOCK or p21 to be positive for G1/S
transition ("value 1"), while G1/S ratios higher than
MOCK or p21 were considered negative ("value 0"). For
the knockdowns of CDK4, Cyclin D1, Cyclin E1, ER-α and
c-MYC, we thus observed no G1/S transition (Table 2).
Table 2 summarizes the simulation results for the final
state of the pRB protein and the respective experimental
data. Indeed, 12 out of 17 knockdown simulations were
consistent with experimentally measured pRB activity lev-
els (compare columns 1 and 2 of Table 2). The correlation
is even slightly better with 7-AAD data, as the results of 13
out of 17 simulations were consistent with those of the p-
pRB data (compare columns 1 and 3 of Table 2). How-
ever, the simulations of ER-α, c-MYC and Cyclin E1
knockdowns gave results that are inconsistent with both
types of the experimental data, pointing out the limits of
our current model, which we will address in the next sec-
tion. Altogether, our results suggest that Cyclin D1, CDK4,
Cyclin E1, ER-α and c-MYC, but neither the combinatorial
targeting of ERBB family receptors nor of key components
of the MAPK (MEK1) and the survival pathways (AKT1)
should be considered as potential targets for further test-
ing in our de novo trastuzumab resistant model cell sys-
tem.
Table 2: Comparison of simulation results with experimental data (p-pRB protein data and 7-AAD DNA data).
Simulated p-pRB data 7-AAD data Improved rules
MOCK 11 1 1
AKT1 11 1 1
MEK1 11 1 1
CDK2 11 1 1
CDK4 00 0 0
p21 11 1 1
p27 11 1 1
Cyclin D1 00 0 0
ERBB2_3 11 1 1
ERBB1_3 0/1 11 0/1
ERBB1 1 0 1 1
ERBB1_2 0/1 0 1 0/1
IGF1R 1 0 1 1
CDK6 0 0 1 0
ER-α 1 00 0
c-MYC 1 00 0
Cyclin E1 1 00 1
The first column ("Simulated") corresponds to the results of knockdown simulations for the initial logical model, while the last column ("Improved 
rules") displays the results obtained with the revised model (improved logical rules for Cyclin D1 as shown in Table 1). In the "Simulated", "p-pRB 
data" and "Improved rules" columns, the value "1" denotes the phosphorylation of pRB (G1/S transition) and "0" denotes the lack of 
phosphorylation (no G1/S transition). In the "7-AAD data" column, the value "1" denotes a low ratio of G1/S (G1/S transition) and "0" denotes a 
high G1/S ratio (no G1/S transition). Bold numbers emphasize the knockdowns for which simulations and both experiments agree. Normal 
numbers correspond to the knockdowns for which experiments led to different values, one of them being met by our simulation results. In the case 
of ERBB1_3 knockdown, one of the two existing stable states meets the concordant experimental result. The final state depends on the choice of 
the initial conditions, but these are difficult to fully specify (a similar situation occurs for the ERBB1_2 knockdown). Finally, Italic numbers denote 
the knockdowns for which simulation data differ from the results of both experiments.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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Refinement of logical rules and network reconstruction 
based on quantitative protein data
To find out whether the observed discrepancies between
our network model and the experimental data were due to
the incorporation of incorrect logical rules, missing inter-
actions, or even missing components in our literature-
based network, we next refined the logical rules and per-
formed a network reconstruction that was based on quan-
titative protein data.
Extracting information about combinatorial regulatory
effects of different proteins affecting a given component is
much more difficult than extracting information about
individual interactions from the literature. We have thus
systematically evaluated modifications of the logical rule
with respect to model prediction capacity. In particular,
the discrepancy between the simulation results and exper-
imental counterparts for c-MYC and ER-α knockdowns
could be solved by changing the logical rules associated
with the Cyclin D1 node. We tested several combinations
for the logical rules on ER-α, c-MYC and Cyclin D1. A
minor modification of the model enabled us to recover
the correct behaviour for the two loss-of-functions: ER-α
and c-MYC (with a stable state having pRB = 0), while
conserving all the behaviour for all other proteins. The
original rules assumed that the presence of one activator
is sufficient (the OR connecting all 4 variables in Table 2).
This is the loosest rule that can be defined for a node that
is activated by several regulators. The modified rule (Cyc-
lin D1 = 1 when ER-α AND c-MYC AND (AKT1 OR MEK1)
is more restrictive as this states that that ER-α AND c-MYC
together with AKT1 OR MEK1, are required to activate
Cyclin D1. The biological implication of this change is
that ER-α, c-MYC and (MEK1 or AKT1) proteins should
act together to make the cells pass through S-phase and
proliferate. In addition, although both transcription fac-
tors are necessary at the same time, the function of the one
of the signaling molecule, AKT1 or MEK1, can be compen-
sated in the cell, but not of the two at the same time. So,
our results may propose a more comprehensive logic for
the regulation of Cyclin D1 in our model cell system.
These results may hint that control of Cyclin D1 is a
sequential event (AKT1 or MEK1 → ER-α → c-MYC) and
can exclude the alternative edges from ER-α, MEK1 or
AKT1 to Cyclin D1. We are thus left with just one knock-
down simulation (Cyclin E1) disagreeing with the experi-
mental data.
In the next step, we wanted to test if the discrepancy
observed in the case of Cyclin E1 knockdown could be
attributed to some missing interactions among the regula-
tory components considered in our logical model. In
order to address this discrepancy and also to examine cell
line specific regulations, we further quantified the activa-
tion and expression levels of most of the network ele-
ments for individual and combinatorial network protein
knockdowns using reverse phase protein arrays. In total,
we quantified the changes in expression of nine network
proteins, as well as the phosphorylation levels of ERK1/2
and AKT1. Some proteins could not be included in these
measurements because of the lack of antibodies suitable
for RPPA. As for the pRB experiments, we examined the
effect of EGF stimulation on the other network proteins
for each knockdown, compared to MOCK. The heatmaps
in Figure 6 show the significant changes, at the expression
or activation level of the proteins before EGF stimulation
(Figure 6A) and 12 h after EGF stimulation (Figure 6B).
Expression and phosphorylation levels either confirmed
known interactions or inferred novel ones (Figure 6B).
The resulting interactions define the network presented in
Figure 7. A jackknife procedure (see Methods section) was
used to eliminate putative indirect edges, which could be
explained by a path along other edges, and only edges
having a jackknife probability greater than 50% were kept
(Figure 7). In the graph, solid black arrows indicate
inferred direct or indirect interactions which are also sup-
ported by published data, whereas the dotted grey arrows
denote novel regulations having been identified for the
HCC1954 reference cellular system. As a result, we
inferred most of the interactions considered in our litera-
ture-based network from the experimental data for trastu-
zumab resistant HCC1954 cells, although some of them
have opposite directions. One should also take into
account that drawing edge directions from biological liter-
Determination of knockdown efficiency and specificity of siRNAs in the HCC1954 cell system Figure 4 (see previous page)
Determination of knockdown efficiency and specificity of siRNAs in the HCC1954 cell system. A. qRT-PCR 
results showing the knockdown efficiency of 20 nM pools of four siRNAs for each gene in the network (50 nM siRNA for 
ESR1). ACTB and HPRT1 were used as house-keeping controls. MOCK stands for the samples which were treated only with 
Lipofectamine transfection reagent. B. Western blots for the determination of knockdowns for the network elements at pro-
tein level. Since dimers of ERBB family members are accepted as functional units, we used combinatorial RNAi (knockdown of 
two genes simultaneously) to produce knockdowns of such dimers. C. qRT-PCR results showing the knockdown efficiency and 
effect of one member of ERBB receptor family siRNA on the other two members of the family. Both pools of four individual 
siRNAs per gene and only one individual siRNA per gene were used. The concentration of siRNAs was 20 nM. ACTB was used 
as house-keeping control. D. Western blots showing the knockdown efficiency and cross reactivity of siRNAs at protein level. 
β-actin was taken as loading control.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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ature is usually a daunting task. Indeed, edge directions,
when indicated, are often not well defined or even errone-
ous. Additionally, there can be cell line specific differences
or thus far unknown feedback mechanisms, for example a
feedback from Cyclin D1 to MEK1 or from ER-α to AKT1.
It is, therefore, not really unlikely to see edges that link in
the direction opposite to the expected. Hence, although
this approach demonstrates the feasibility of network
reverse engineering at protein level using robust and
quantitative protein array data, the resulting network was
no help to solve the discrepancy observed for Cyclin E1
knockdown, thereby leaving a gap in our knowledge in
the regulation or regulatory effects of this component. To
sum up, our network inference approach provided us with
the knowledge that the most regulations which were
obtained from the literature were also present in our tras-
tuzumab cell system and novel regulations might have
potential role in the observed phenotype of the cells.
Combinatorial targeting of c-MYC or EGFR in combination 
with ERBB2 using small chemical inhibitors in sensitive and 
resistant cells
In order to verify the RNAi results and to validate the
potential targets in our de novo resistant cell system, we
applied small chemical inhibitors against c-MYC (10058-
F4) and EGFR (gefitinib), alone and in combination with
trastuzumab, and examined the growth of trastuzumab
resistant HCC1954 cells compared to sensitive SK-BR-3
and BT474 cells. Administration of the c-MYC inhibitor
alone resulted in reduced pRB phosphorylation in all
three cells lines (Figure 8A, left panel), and its application
alone or in combination with trastuzumab also reduced
the growth of these cell lines (Figure 8B, middle panel).
The results were verified using real-time impedance meas-
urements over four days (Figure 8C, right panel), provid-
ing a time-lapse profile of the growth rates. The resulting
data demonstrate that the reduced growth rates of cells
treated with the c-MYC inhibitor was independent from
trastuzumab resistance and thus support the RNAi results
shown in Figure 5A and 5B.
Because combinatorial targeting of ERBB receptors is
already in clinical use (e.g. lapatinib), we next targeted
ERBB1 and ERBB2 receptors in single and combinatorial
settings and compared the outcome in the de novo resist-
ant HCC1954 cell line with the trastuzumab sensitive cell
lines. First, we examined the downstream effectors of
ERBB receptors (ERK1/2 and AKT1) and of pRB after treat-
ment with trastuzumab or gefitinib (targets ERBB1) (Fig-
ure 8B, left panel). In HCC1954 cells, no reduction in the
expression levels of EGFR/ERBB2 or phosphorylation lev-
els of their downstream signal mediators was observed for
both treatments. However, reduced pRB phosphorylation
was observed in gefitinib-treated HCC1954 cells. Both,
the WST-1 viability assay and real-time impedance meas-
urements demonstrated that trastuzumab resistant
HCC1954 cells were also resistant to gefitinib treatment
alone or in combination with trastuzumab. (Figure 8B,
middle and right panel).
In SK-BR-3 cells, AKT1 and pRB phosphorylation levels
were lower after trastuzumab treatment, and pRB phos-
phorylation was reduced after incubation with gefitinib.
In BT474 cells, a strong reduction in AKT and ERK1/2
phosphorylation was measured after gefitinib treatment,
while no such an effect was evident for trastuzumab treat-
ment (Figure 8B, left panel). Real-time impedance meas-
Analysis of the effects of knockdowns on G1/S transition in  trastuzumab resistant HCC1954 cells Figure 5
Analysis of the effects of knockdowns on G1/S transi-
tion in trastuzumab resistant HCC1954 cells. A. Phos-
phorylation state of pRB (output of the network) after 12 
hour EGF stimulation (input of the network). Box plots show 
the quantitative phosphorylation of pRB protein for the 
knockdown of each network protein compared to MOCK 
(only transfection reagent, no siRNA). B. G1/S ratio after 18 
hours of EGF stimulation for corresponding knockdowns 
compared to MOCK (solid line) and p21 knockdown (dotted 
line) using 7-AAD DNA staining.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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urement showed for the SK-BR-3 cells that combinatorial
targeting of EGFR and ERBB2 had a strong additive effect
to reduce cell proliferation (Figure 8B, right panel). This
additive effect was also visible for BT474 cells although it
was not as strong as in SK-BR-3 cells. These data support
our RNAi results, suggesting that the combinatorial target-
ing of the EGFR and ERBB2 with gefitinib and trastuzu-
mab, respectively, might not be effective to sensitize the
cells to trastuzumab treatment in de novo trastuzumab
resistance. However, these drugs in combination might
lead to an improved outcome in sensitive cells, and poten-
tially also in tumors, as compared to applying them indi-
vidually.
Discussion
In the present study, we have applied a systems biology
approach to identify alternative targets in de novo trastuzu-
mab resistant breast cancer. While several studies have
dealt with mechanisms leading to acquired trastuzumab
resistance, there has been no comprehensive study that
searched for targets alternative to ERBB2 in de novo trastu-
zumab resistance. Since the aim of cancer therapy is to
reduce the growth rate of cancer cells, and trastuzumab
resistant breast cancer cells escape cell cycle arrest during
treatment, we focused on a protein network that connects
ERBB signaling to G1/S phase transition, in order to deter-
mine new potential targets for perturbation. In contrast to
previous studies, which had focused on the involvement
of an individual protein in the resistant phenotype of the
cells, we aimed to examine the roles of each protein in the
context of their interactions at a protein network level.
Several modeling studies about the ERBB receptor-regu-
lated signaling pathways have been published recently
[30,31]. These studies considered the activation of key
intermediates (ERK1/2 and AKT) upon EGF and HRG
stimulation and proposed differential dynamical models
for these pathways. Likewise, various models have been
proposed for the control of the mammalian cell cycle
[18,22,32]. In our study, we combined these two cellular
processes into one coherent network to find novel strate-
gies for breast cancer therapy. First, we derived a logical
network from published data (Figure 3 and Table 1). Sys-
tematic simulations of loss-of-function perturbations
were performed, and the final state of pRB phosphoryla-
tion (the marker for G1/S transition) was determined in
each case. These computational results were then com-
pared with experimental knockdowns, obtained by RNA
Response of network proteins for corresponding knockdowns in trastuzumab resistant HCC1954 breast carcinoma cells (A)  before and (B) after EGF stimulation Figure 6
Response of network proteins for corresponding knockdowns in trastuzumab resistant HCC1954 breast carci-
noma cells (A) before and (B) after EGF stimulation. Heatmaps were drawn for a false discovery rate (FDR) of less 
than 1%.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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interference. While each network component was targeted
by siRNAs in a single knockdown setting, both constitu-
ents of ERBB heterodimers were repressed in a combina-
torial RNAi setting (Figure 4). We quantified the effects of
these knockdowns on pRB phosphorylation with reverse
phase protein arrays (RPPA) (Figure 2 and Figure 5).
Knockdowns of c-MYC, ER-α and Cyclin E1 resulted in a
very strong reduction in pRB phosphorylation compared
to ERBB1, ERBB1/ERBB2, and IGF1R knockdowns (Figure
5A). We then determined the ratio of G1/S to further ver-
ify the effect of these knockdowns on G1/S transition (Fig-
ure 5B). DNA staining enabled us to differentiate the
strong effects of c-MYC, ER-α and Cyclin E1 knockdown
as compared to weaker effects of ERBB1, ERBB1/ERBB2,
and IGF1R knockdowns (Figure 5B).
Consequently, Cyclin D1 and CDK4 were identified as
potential targets from both simulation and experiments.
This result was expected, as in response to an external
stimulus, Cyclin D1 and CDK4 make a complex that
Tentative regulatory interactions inferred from protein expression and activation data for trastuzumab resistant HCC1954  cells Figure 7
Tentative regulatory interactions inferred from protein expression and activation data for trastuzumab resist-
ant HCC1954 cells. The heatmaps in Figure 6B were used to infer the interactions of proteins in the HCC1954 cell system 
with a probability higher than 50%. The numbers next to each arrow indicate the probability of each interaction. Solid black 
arrows denote the interactions (both direct and indirect) supported by published data, whereas dotted grey arrows denote 
novel interactions (compare with Figure 3). Normal arrows denote positive regulations, whereas blunt arrows denote negative 
regulations.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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phosphorylates pRB, and which, in turn, enables G1/S
transition. Accordingly, we found knockdown of these
proteins to result in a significant reduction in the phos-
phorylation of pRB. In contrast, c-MYC, ER-α and Cyclin
E1 were identified by experimental analyses on de novo
trastuzumab resistant cells, but had not been predicted in
the initial network model. After network refinement, c-
MYC and ER-α were also predicted as targets from the
model (Table 1 and 2). Hence, we demonstrated that this
approach enables the reconstruction of phenotype-spe-
cific interactions, which are essential to predict therapeu-
tic strategies.
In addition, missing components in the protein network
can also be inferred. For example, while Cyclin E1 and
CDK2 form a complex, which further phosphorylates the
pRB protein, our experimental data show that only loss of
Cyclin E1, but not of CDK2, significantly repressed phos-
phorylation of pRB (Figure 5A). This result suggests that
CDK2 could be a dispensable component for the G1/S
transition in de novo trastuzumab resistant breast cancer,
as it has previously been shown for colon cancer cells [33].
This observation raises the question which alternative
interaction partners of Cyclin E1 could promote G1/S
transition.
In our study, the transcription factors c-MYC and ER-α
were identified as potential targets to overcome de novo
trastuzumab resistance. Park et al had previously shown
that an amplification of the c-MYC gene is correlated with
ERBB2 overexpression in breast cancer [34]. In trastuzu-
mab sensitive cells, ERBB2-targeted antibodies can inhibit
c-MYC through inhibition of the MAPK and AKT pathway
which, in turn, increases the activity of p27 towards the
CDK2-Cyclin E complex [35]. Here, we demonstrated that
loss of c-MYC activity results in a reduction of the CDK4
level which then results in reduced pRB phosphorylation
(Figure 7). Targeting c-MYC with a specific chemical
inhibitor alone or in combination with trastuzumab also
resulted in a strong reduction in pRB phosphorylation
and cell growth, both in trastuzumab resistant and sensi-
tive cells (Figure 8A). We conclude that targeting c-MYC
alone or in combination with trastuzumab could be an
interesting candidate for a clinical trial. Cross-talk
between ERBB2 signaling and ER-α activation has been
previously reported [36], and an increase in the ERBB2
expression level has been reported in tamoxifen resistant
cells [37]. In this study, we have shown that ER-α is
another possible target in ERBB2 overexpressing and tras-
tuzumab resistant HCC1954 cells. This suggests an inter-
play between ER-α and ERBB2 receptors in the context of
bypassing the effects of drug treatment.
Interestingly, the five novel candidates to be targeted in de
novo trastuzumab resistant breast cancer have one feature
in common: they all either directly (ER-α, c-MYC and
CDK4) or indirectly (Cyclin D1 and Cyclin E1) regulate
the p27 protein, which plays a key role also in acquired
trastuzumab resistance [38]. In addition, our study indi-
cated that combinatorial targeting of either of ERBB1,
ERBB2 and ERRB3 may not enhance sensitivity to trastu-
zumab in de novo resistant patients, although ERBB pro-
teins have been previously considered as promising
targets. These results let us hypothesize that these cell sur-
face proteins (here: ERBB receptors or IGF1R) are decou-
pled from intracellular processes (here: G1/S transition)
in the de novo trastuzumab resistant cell system. Targeting
EGFR alone or in combination with ERBB2 further sup-
ported this notion. While trastuzumab sensitive cells (SK-
BR-3 and BT474) were responding to gefitinib as well as
combination of gefitinib and trastuzumab treatment in an
additive manner, de novo trastuzumab resistant cells
(HCC1954) did not respond at all (Figure 8B). This obser-
vation suggests that combinatorial targeting of cell surface
receptors might be beneficial as it is an uncommon per-
turbation for cells [39], but it should be taken into consid-
eration that this might be cell system- or patient specific.
Effects of c-MYC inhibitor 10058-F4 and EGFR inhibitor gefitinib alone or in combination with trastuzumab on the viability of  resistant (HCC1954) and sensitive (SK-BR-3 and BT474) cells Figure 8 (see previous page)
Effects of c-MYC inhibitor 10058-F4 and EGFR inhibitor gefitinib alone or in combination with trastuzumab on 
the viability of resistant (HCC1954) and sensitive (SK-BR-3 and BT474) cells. A. Left panel: Western blot data show-
ing the phosphorylation state of pRB protein after treatment with c-MYC inhibitor (10058-F4, 80 μM) for 24 hours. Middle 
panel: WST-1 viability assay over 4 days to determine the response of cells to c-MYC inhibitor alone and in combination with 
trastuzumab. DMSO is used as vehicle control. Right panel: Impedance measurement for real-time determination of cell growth 
before (24 hours) and after (72 hours) treatment of cells with c-MYC inhibitor, trastuzumab, and the combination of both 
drugs. The impedance measurements were normalized to the time point where we have added the drugs. The vertical line 
demonstrates the time point of normalization. B. Left panel: Western blot data showing the effect of different concentrations of 
trastuzumab and gefitinib (1 μM) on the expression levels of EGFR and ERBB2 and on the phosphorylation states of ERK1/2, 
AKT and pRB proteins. H2O is vehicle control for trastuzumab and DMSO is for gefitinib. Middle panel: WST-1 assay to deter-
mine the response of cells to gefitinib and gefitinib + trastuzumab. Right panel: The impedance measurement for real-time meas-
urement of cell growth before (24 hours) and after (72 hours) treatment of cells with gefitinib, trastuzumab and combination of 
both drugs. Normalization of cell index is as in A.BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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According to our results, targeting EGFR with siRNAs
alone resulted in an efficient knockdown at the mRNA
level; however, no reduction was observed at the protein
level (Figure 4). This phenomenon might be explained by
the stabilization of EGFR after dimerization with the over-
expressed ERBB2 receptor. Complementary to this obser-
vation, knocking down ERBB2 resulted in reduced EGFR
expression at the protein level, although no reduction of
EGFR was observed at the mRNA level (Figure 4). These
data demonstrate an explicit dependence of EGFR protein
abundance on ERBB2 expression, and should be kept in
mind when EGFR is targeted in cancer therapies. This
observation is independent of trastuzumab sensitivity,
but is highly influenced by the ERBB2 expression level
(Figure 1 and Additional file 1, Figure 3).
It should be noted that the logical formalism used in this
work clearly caricatures subtle dose effects into all-or-
none responses for all the components considered. The
resulting logical model should thus be taken as a first step
in the formalisation of the regulatory network involved in
trastuzumab resistance. However, it is appropriate to
translate qualitative information and compare the behav-
iour of alternative network wirings or logical rules with
data sets for unperturbed and perturbed situations. Once
the regulatory wiring and the logical rules be reasonably
established, it will be possible to take advantage of multi-
level logical modeling extensions, or yet to translate our
Boolean models into more quantitative formalisms (e.g.
ordinary differential equations, or yet hybrid or stochastic
Petri nets).
Conclusion
We constructed a literature-based protein network and
combined computational simulations, validation experi-
ments using RNAi, as well as chemical inhibitors, and net-
work inference based on proteomic data, in order to
identify novel targets with potential for individual and
combinatorial therapies in breast cancer. Our concept to
combine experimental and computational biology dem-
onstrated the strengths and limitations of using literature-
based models for simulations of therapeutic strategies.
Furthermore, this study led us to select c-MYC as a candi-
date to be tested in in vitro and in vivo models, regarding
future treatments for breast cancer which is de novo resist-
ant to trastuzumab. Our results also suggest that combina-
torial targeting of key ERBB receptors might have better
outcome than individual therapies in trastuzumab sensi-
tive cells, but not in de novo trastuzumab resistant cells.
Methods
Cell Culture
Five human breast cancer cell lines (HCC1954, SK-BR-3,
MDA-MB-231, BT474 and MCF-7) as well as the normal
breast epithelial cell line MCF-12A were obtained from
ATCC (Manassas, VA). HCC1954 cells (CRL-2338) were
cultured in RPMI 1640 Modified Medium (ATCC), SK-BR-
3 cells (HTB-30) in McCoy's 5a medium (GIBCO BRL),
and MDA-MB-231 cells (HTB-26) in Leibovitz's L-15
medium (Sigma). BT474 cells (HTB-20) were cultured in
DMEM medium, MCF-7 cells (HTB-22) in Eagle's Minim-
ial essential medium, and MCF-12A cells (CRL-10782) in
a medium containing a 1:2 mixture of Dulbecco's Modi-
fied Eagle's Medium and Ham's F12 medium. All media
were supplemented with 50 U/mL penicillin, 50 μg/mL
streptomycin sulphate, 1% non-essential amino acids and
10% fetal bovine serum (all media and supplements from
Gibco BRL). Additionally, 2.2 g/L sodium bicarbonate
was supplemented for MDA-MB-231 cells. Media for
BT474 cells were supplemented with 10% NCTC
medium, 500 μl bovine insulin and 100 μl Oxalic acid, for
MCF-7 cells we added 0.01 mg/mL bovine insulin, and
such for MCF-12A cells were supplemented with 20 ng/
mL EGF, 100 ng/mL cholera toxin, 0.01 mg/mL bovine
insulin, and 500 ng/mL hydrocortisone. The cells were
incubated at 37°C with 5% CO2 and split 2–3 times per
week in a 1:3 ratio for no more than 20 passages. All cell
lines were validated by genotyping.
3-D cell culture
HCC1954 and SK-BR-3 cells were cultured in 8-well
chamber slides in order to examine the effect of trastuzu-
mab on proliferation. Geltrex (Invitrogen, Carlsbad, CA)
was thawed on ice and 40 μL was pipetted per well and left
for 30 min at 37°C to solidify. HCC1954 and SK-BR-3
(5.000 cells/well) cells were seeded in medium supple-
mented with 1:50 Geltrex and EGF (BD Biosciences), and
with or without trastuzumab (100 nM) (Roche, Penzberg,
Germany). The cells were incubated at 37°C and 5% CO2
for eight days, and medium was changed after 4 days.
siRNA transfections and EGF stimulations
HCC1954 cells were seeded at a number of 7 × 105 cells
per 10 cm petri dish in antibiotic free medium. Conflu-
ency of the cells was 50–60% at the day of transfection.
Sequences of siRNAs are given in Additional file 1, Table
2. Twenty nM of siRNA (except ESR1 siRNA (50 nM))
(Dharmacon, Lafayette, CO) and 25 μL of Lipofectamine
2000™ (Invitrogen, Carlsbad, CA) were diluted separately
in reduced-serum medium OptiMEM (Gibco BRL) and
incubated for 5 minutes at RT. The two solutions were
then mixed and incubated for 20 minutes at RT. The
siRNA-Lipofectamine 2000™ mixture was then added to
the cells and the dishes were shaken by gentle rocking.
MOCK transfected cells were treated with Lipofectamine
2000, but no siRNA was added. The cells were incubated
at 37°C and 5% CO2 for 24 hours. After incubation, cells
were starved by Dif-3 (30 μM) (Sigma) for 22 hours in
medium containing 10% FBS. Cells were further starved
in 0% FBS medium for 2 hours. After 24 hours of starva-BMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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tion, cells were stimulated with EGF (25 ng/mL) for 6, 12,
18 and 24 hours.
Cell lysis and Western blotting
At each time point, medium was removed and cells were
washed with ice-cold PBS containing 10 mM NaF and 1
mM Na4VO3. Lysis of cells was performed on ice by scrap-
ing or by cold trypsinization, and shaking on over-head
shaker for 15 minutes at 4°C with 70 μl M-PER lysis buffer
(Pierce, Rockford, IL) containing protease inhibitor Com-
plete Mini (Roche, Basel), anti-phosphatase PhosSTOP
(Roche, Basel), 10 mM NaF and 1 mM Na4VO3. Protein
concentrations were determined with a BCA Protein Assay
Reagent Kit (Pierce, Rockford, IL). Proteins were denatur-
ated with 4× Roti Load (Roth, Karlsruhe, Germany) at
95°C for 5 minutes, and 12 μg proteins were loaded in
every lane. Protein samples were separated by 8% or 12%
SDS PAGE, electroblotted to PVDF membranes (Amer-
sham Biosciences, USA) and exposed to primary antibod-
ies. A list of antibodies is given in Additional file 1, Table
3, together with their dilutions. Horseradish peroxidase
conjugated anti-mouse or rabbit antibodies (Amersham
Biosciences, USA) were used as secondary antibodies and
signals were detected by enhanced chemiluminescence
(Amersham Biosciences, USA).
TaqMan (qRT-PCR)
Total RNA was extracted from the cells by using the Invi-
sorb Spin cell RNA mini kit (Invitek GmbH, Berlin, Ger-
many), and single-stranded cDNA was transcribed with
the RevertAid H Minus First Strand cDNA Synthesis kit
(Fermentas, St. Leon-Rot, Germany). Ten nanograms of
total RNA were used for each reaction. qRT-PCR for target
genes and housekeeping genes ACTB and HPRT1 was per-
formed with the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems, Weiterstadt, Germany),
applying probes of the Universal Probe Library (Roche,
Penzberg, Germany). Primers were synthesized by MWG
(Ebersberg, Germany). Sequences of primers and the
respective UPL probe numbers are given in Additional file
1, Table 4.
Reverse Phase Protein Arrays (RPPA)
Cell lysates were prepared as for Western Blotting. All
lysates were adjusted to a total protein concentration of 3
μg/μl. Cell lysates were mixed 1:2 with 2× Protein Array-
ing Buffer (Whatman, Brentfort, UK) to yield a final pro-
tein concentration of 1.5 μg/μL. The samples were printed
with a non-contact piezo spotter, sciFlexxarrayer S5 (Sci-
enion, Berlin, Germany), in four replicate spots per sam-
ple and subarray, and two subarrays per slide onto
nitrocellulose coated ONCYTE-slides (Grace Bio Labs,
Bend, USA). Twenty replicate slides were produced per
run. Approximately 2.25 ng total proteins were delivered
per spot. As spotting control, the total protein content of
all spots was determined for two replicate slides with the
FAST Green FCF assay. All antibody signals were normal-
ized according to their total protein content. Slides were
blocked over night and target proteins were detected with
specific primary antibodies (Additional file 1, Table 3)
using a protein array incubation chamber (n1-quadrat,
Metecon, Mannheim, Germany). Detection of primary
antibodies was carried out with near-infrared (NIR)-dye
labeled secondary antibodies and visualized using an
Odyssey scanner (LI-COR, Lincoln, USA). Signal intensi-
ties were quantified using Odyssey 2.0 software, corrected
for spot-specific background signals and normalized for
their total protein concentrations.
7-AAD staining and analysis
Directly after siRNA transfections, cells were synchronized
for 24 hours (see above), and stimulated with EGF for 18
hours. Then, cells were trypsinized, washed once with PBS
and centrifuged. Ice cold methanol was added to the cell
pellets while vortexing the FACS tube. After incubation of
cells at -20°C overnight, methanol was removed and 250
μl of 7-AAD (1:40 dilution) (Calbiochem, Darmstadt,
Germany) was added to each tube and incubated for 1.5
hours at 4°C in the dark. The measurement was done by
flow cytometry (FACS Calibur, BD Biosciences) using the
FL3 channel for 7-AAD staining. Analysis of the 7-AAD
results was performed using CellQuest Pro software with
the histogram statistics option and a gate on the main cell
population.
WST-1 cell viability assay
HCC1954 cells were seeded at a number of 2,500 cells/
well in 96 well format in 100 μL of 10% FBS medium
without antibiotics. After 24 hours of incubation, cells
were washed once with PBS and then incubated with 200
μl of either trastuzumab (100 nM) (Roche, Penzberg, Ger-
many) or gefitinib (1 μM) (Biaffin, Kassel, Germany) or c-
MYC inhibitor 10058-F4 (80 μM) (Sigma) containing
10% FBS medium. Cells were incubated for 24 hours and
each day 20 μl of WST-1 reagent (Roche, Basel) was pipet-
ted to the cells. Absorbance was measured at 450 nm after
2.5 hours with a SpectraMAX 190 (Molecular Devices,
UK). The WST-1 assay was performed over four days with
one measurement taken on everyday.
Real-time cell-electrode impedance measurements
One hundred microliters of growth medium was added to
the wells of E-plates (Roche, Penzberg) for background
measurements. Then, 100 μL of HCC1954, SK-BR-3 and
BT474 cell suspensions were added at a number of 8,000
(for HCC1954 cells) and 10000 (for SK-BR-3 and BT474)
cells/well. E-plates were incubated at room temperature
for 30 minutes; then transferred to the holder and incu-
bated at 37°C with 5% CO2. The continuous impedance
measurement was recorded and converted to a cell indexBMC Systems Biology 2009, 3:1 http://www.biomedcentral.com/1752-0509/3/1
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(CI). After 24 hours, the chemical inhibitors (10058-F4
(80 μM) and gefitinib (1 μM) or/and trastuzumab (100
nM) were added to the respective wells and impedance
measurements were continued for 72 hours. Results were
analyzed using RTCA Software 1.0 (Roche, Penzberg, Ger-
many).
Modeling, simulations and data analysis
Logical modeling and simulations
A logical model is defined by a regulatory graph, where the
nodes and arcs represent the regulatory components and
interactions, respectively. The dynamical behavior of each
component is then defined by logical functions (also rep-
resented in terms of logical parameters), which associate a
target value for this component depending on the level of
its regulators. The dynamics of the system is represented
in terms of a state transition graph, where the nodes
denote states of the system (i.e., a vector giving the levels
of activity of all components), and the arcs denote state
transitions (i.e., a change in the value of one or several
component(s), depending on the values of the relevant
logical functions or parameters). In state transition
graphs, terminal nodes correspond to "stable states". Note
that, for most of the conditions considered, our ERBB
receptor regulated G1/S model has a single stable state.
The Boolean model of ERBB signaling network was
defined and analyzed using the GINsim software [22,23].
Beginning with relevant initial states, simulations using
the logical rules defined in Table 1 was performed. For
MOCK case, the initial levels of EGF, all ERBBs, p21 and
p27 were set to 1, whereas Cyclin D1 was set to 0. The ini-
tial levels of the other proteins were left undefined, mean-
ing that both possible levels were considered. A
knockdown can be simulated in GINsim by setting the
corresponding protein's initial level and its maximal value
to 0. The resulting parameterized model and all simula-
tions can be downloaded from the model repository
referred at the GINsim web page: http://gin.univ-mrs.fr/
GINsim/model_repository.html.
Analysis of knockdown responses
Statistical significance of protein expression changes and
pRB phosphorylation due to knockdowns via RNA inter-
ference were calculated using the ANOVA method: protein
expression ~ knockdown effect + biological replicate factor +
error A multiple testing correction was performed using
Benjamini-Hochberg's method [40] with a false discovery
rate (FDR) significance cut off of 1%.
Network inference
Whenever a knockdown significantly affected the expres-
sion of another protein with an FDR < 1%, an edge was
drawn. Then a transitive reduction of the graph was calcu-
lated (i.e. eliminating putative indirect edges, which could
also be explained by another path in the graph [41]. Since
the transitive reduction for graphs with cycles is not
unique and depends on the ordering of the nodes, we
implemented a jackknife procedure, i.e. we left out each
node once, estimated the network, and finally counted for
each edge the frequency of the occurrence among all jack-
knife samples. The corresponding jackknife probability is
reported at each edge. We also performed the multiple
testing corrections separately within each sample of the
jackknife procedure, since the false discovery rate depends
on the distribution of all raw p-values, which may change
with the differing gene selection in each jackknife sample.
The R source code is available from the authors upon
request. Only the edges having a jackknife probability
greater than 50% were kept.
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